The offshore energy services firm anticipates robust Q1 2026 revenue, signaling sustained demand in the sector. SBM Offshore announced expectations for robust revenue growth in Q1 2026 during its earnings call. The company attributed the outlook to strong project execution
The biopharma firm maintains its 2026 revenue guidance as investors await Phase II results for its Alzheimer’s treatment candidate. Acadia Pharmaceuticals reaffirmed its 2026 total revenue guidance of $1.22 billion to $1.28 billion. The projection remains unchanged as the
The company forecasts mid-single-digit declines in dealer wholesale while outlining growth targets and capital return plans. ACV Auctions Inc. announced a 2026 revenue target of $845M to $855M, alongside a $100M share repurchase authorization. The guidance reflects expecta
New to Bybit? Register and trade to claim $20 NVDAX! That’s not all — new users can unlock up to $100 welcome gifts. One Bybit, Trade All. Easy like a game 🔥 #Bybit #NewFinancialPlatform
The benchmark index rose on broad-based buying, marking its strongest daily performance in over two weeks. Indonesia’s IDX Composite Index climbed 1.19% to close at a two-week high, led by gains across financials, consumer staples, and energy sectors. The advance followed
Investors react positively to reports of progress in U.S.-Iran negotiations, lifting regional market sentiment. European equities climbed in early trading as optimism over a potential U.S.-Iran peace deal reduced geopolitical risk. Major indices in Germany, France, and the
BPIFrance's placement of 6.5 million Technip Energies shares weighs on the stock, diluting ownership by 5.6%. Technip Energies shares fell after BPIFrance placed 6.5 million shares, representing 5.6% of the company’s capital. The sale, conducted at €14.50 per share, was ex
Analysts cite positive clinical trial progress as the key driver for reiterating the stock's bullish outlook. Guggenheim reaffirmed its Buy rating on EyePoint Pharmaceuticals (EYPT) following recent advancements in the company’s clinical trials. The firm highlighted progre
Stifel reaffirms its bullish stance on Elanco Animal Health with a $32 target amid ongoing market analysis. Stifel reiterated its Buy rating on Elanco Animal Health (ELAN) and set a $32 price target for the stock. The decision reflects continued confidence in the company’s
Henkel Co KGaA AG reports stronger Q1 2026 results driven by strategic acquisitions, lifting investor confidence. Henkel Co KGaA AG shares rose following its Q1 2026 earnings call, as strategic acquisitions bolstered financial performance. The company highlighted improved
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.